Search
/ca/our-science/source-materials-overview
ALK Source Materials, A unique production approach, source-materials-overview-banner.jpg
,
Producing allergy immunotherapy products, Left
,
From pollens to finished products, RAW MATERIALS, LEARN MORE ABOUT ALK SOURCE MATERIALS FACILITIES, source-materials-overview-line1.jpg, GROW, COLLECTION, LEARN MORE ABOUT POLLEN COLLECTION, source-materials-overview-line2.jpg, HARVEST, MANUFACTURING STAN…,
ALK Allergen Extract Source Material Production, About ALK Extract Manufacturing
/ca/fr/notre-science/apercu-des-matieres-premieres
Matières de base d'ALK, Une stratégie de production unique, source-materials-overview-banner.jpg
,
Production des produits d'immunothérapie allergénique, Left
, 4
Des pollens aux produits finis, MATIÈRES PREMIÈRES, EN SAVOIR PLUS SUR LES INSTALLATIONS DE MATIÈRES DE BASE D’ALK, source-materials-overview-line1.jpg, Grandir, RÉCOLTE, EN SAVOIR PLUS SUR LA RÉCOLTE DE POLLEN, source-materials-overview-line2.jpg, Récol…,
Production des matières premières des extraits d'allergènes d'ALK, About ALK Extract Manufacturing
/ca/our-science/making-history
Research pioneers, Shaping the future of allergy treatment since 1923, making-history-banner.jpg
,
ALK’s history dates back to 1923 when the first allergen extracts were produced at the pharmacy of the Copenhagen University Hospital (Rigshospitalet)
/ca/fr/notre-science/science-novatrice
Pionniers de la recherche, Chef de file du traitement des allergies depuis 1923, making-history-banner.jpg
,
Les origines d'ALK remontent à 1923, alors que les premiers extraits d'allergènes étaient produits à la pharmacie de l'hôpital de l'Université de Cope
/ca/about-alk/owners
Owners, Our owners’ contribution to society, rails_0.jpg
,
A stable ownership structure, The Lundbeck Foundation (Lundbeckfonden) has a 40.3% interest (including A shares) and the Danish pension fund ATP has a 5.1% interest. Of the 30 larg
,
Examples of grants from Lundbeckfonden, 2013, 2014, 2015
,
Overview of the Lundbeck Foundation, ALK’s controlling shareholderThe Lundbeck Foundation is the largest and controlling shareholder of ALK, owning 67% of the votes (40% of the capital).D, Left, Read more about the Lundbeck Foundation
/ca/our-science
Allergy pioneers, Breaking new ground, pioneering-allergy-research-banner.jpeg
,
In the fight against allergy, science leads the way, and ALK has spent nearly a century pushing back the frontiers of knowledge with the aim of helpin
,
Investing in understanding and innovation, Treatment for four of the most common allergies, Read more about our pipeline, Evidenced-based treatment, Read more about our clinical trials, Ground-breaking clinical trials, Read more about how allergy immunoth…